Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin

Trial Profile

Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Atorvastatin (Primary) ; Seladelpar (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 14 Apr 2018 Results assessing the mechanism of action of Seladelpar in PBC and NASH patients from phase II studies (NCT00701883, NCT02472535, NCT02609048 and NCT02955602) presented at The International Liver Congress 2018
    • 01 Feb 2012 Results assessing the effect of treatment lipoprotein particle subfractions published in Atherosclerosis.
    • 14 Jun 2009 Results presented at the 15th International Symposium on Atherosclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top